Leerink Partnrs Comments on Alumis FY2029 Earnings

Alumis Inc. (NASDAQ:ALMS - Free Report) - Equities researchers at Leerink Partnrs issued their FY2029 earnings estimates for Alumis in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will post earnings of ($1.61) per share for the year. The consensus estimate for Alumis' current full-year earnings is ($8.45) per share.

A number of other equities analysts have also recently commented on ALMS. HC Wainwright reduced their price target on Alumis from $26.00 to $19.00 and set a "buy" rating for the company in a report on Friday. Oppenheimer started coverage on shares of Alumis in a report on Thursday, January 30th. They issued an "outperform" rating and a $32.00 price objective on the stock. Cantor Fitzgerald restated an "overweight" rating on shares of Alumis in a research note on Thursday, November 14th. Robert W. Baird started coverage on shares of Alumis in a research note on Thursday, October 31st. They issued an "outperform" rating and a $25.00 price target on the stock. Finally, Baird R W upgraded shares of Alumis to a "strong-buy" rating in a research report on Thursday, October 31st. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Alumis presently has a consensus rating of "Buy" and a consensus target price of $26.57.

Alumis Stock Performance

ALMS stock traded down $0.85 during trading hours on Thursday, reaching $4.82. The stock had a trading volume of 421,879 shares, compared to its average volume of 216,766. The stock has a 50-day simple moving average of $7.80 and a 200 day simple moving average of $10.19. Alumis has a fifty-two week low of $4.74 and a fifty-two week high of $13.53.

Institutional Trading of Alumis

Several large investors have recently made changes to their positions in the company. Millennium Management LLC bought a new stake in Alumis during the second quarter worth $3,376,000. Towerview LLC raised its holdings in shares of Alumis by 22.6% during the 3rd quarter. Towerview LLC now owns 380,000 shares of the company's stock worth $4,058,000 after buying an additional 70,000 shares in the last quarter. Charles Schwab Investment Management Inc. bought a new stake in shares of Alumis during the 3rd quarter worth $1,160,000. BNP Paribas Financial Markets bought a new position in Alumis in the third quarter valued at about $27,000. Finally, MetLife Investment Management LLC acquired a new position in Alumis during the third quarter worth about $89,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.